Please ensure Javascript is enabled for purposes of website accessibility

Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19

By Brian Orelli, PhD – Apr 2, 2020 at 8:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Both diseases involve an overactive immune system.

Cancer and a viral infections wouldn't seem to have much in common, but Incyte (INCY -1.55%) is testing its blood cancer drug Jakafi in patients with COVID-19, the disease caused by the new coronavirus.

The connection is that Jakafi helps patients with a blood cancers by inhibiting immune cells -- and some of the most deleterious effects of COVID-19 come from the immune system, which can go haywire while attacking the coronavirus and attack the patients' own cells. The immune system has a positive-feedback loop -- perpetuated by molecules called cytokines -- which can result in what's called a cytokine storm if the immune system isn't put in check.

Other companies with drugs that treat autoimmune diseases, such as Regeneron (REGN -1.93%) and Sanofi's (SNY -0.45%) Kevzara and Roche Holding's (RHHBY -1.53%) Actemra are also being tested for their ability to dampen the immune complications in COVID-19 patients.

Patient and her doctors in a restricted area

Image source: Getty Images.

Incyte is working with the Food and Drug Administration to start a phase 3 clinical trial, dubbed Ruxcovid, to test Jakafi plus standard of care, compared to standard of care alone. Outside the U.S., the trial will be run by Incyte's partner Novartis.

Given the urgent nature of the disease, Incyte is making the drug available under an emergency expanded-access program in the U.S. for severe COVID-19 patients experiencing a cytokine storm.

"Our intent is to build on emerging evidence from independent studies to further establish the role [Jakafi] could play in balancing immune response to the infection and therefore potentially improving outcomes of patients with COVID-19 associated cytokine storm," said Steven Stein, Incyte's chief medical officer.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Incyte. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Incyte Corporation Stock Quote
Incyte Corporation
INCY
$66.61 (-1.55%) $-1.05
Sanofi Stock Quote
Sanofi
SNY
$38.00 (-0.45%) $0.17
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.11 (-1.53%) $0.64
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$691.82 (-1.93%) $-13.60
Novartis AG Stock Quote
Novartis AG
NVS
$76.57 (0.33%) $0.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.